Evaluation of TEG 6S PM® During Cardiopulmonary Bypass to Detect Postoperative Biological Coagulopathy

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
CoagulopathyCardiopulmonary BypassCardiac Surgery
Interventions
DIAGNOSTIC_TEST

In vitro medical diagnostic device TEG6s® Platelet Mapping

"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."

Trial Locations (1)

34295

Département d'Anesthésie Réanimation cardio-thoracique - Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT06230640 - Evaluation of TEG 6S PM® During Cardiopulmonary Bypass to Detect Postoperative Biological Coagulopathy | Biotech Hunter | Biotech Hunter